CFM
TRDA icon

Cornerstone Financial Management’s Entrada Therapeutics TRDA Stock Holding History

Cornerstone Financial Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$670 Hold
91
– – ﹤0.01% 1227
2026
Q1 		$1.15K Hold
91
– – ﹤0.01% 918
2025
Q4 		$935 Buy
+91
New +$767 ﹤0.01% 962

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Cornerstone Financial Management's TRDA Position: Q2 2026 in Review

Cornerstone Financial Management held its Entrada Therapeutics (TRDA) position steady in Q2 2026 at 91 shares worth $670. The position accounts for ﹤0.01% of the portfolio, ranked #1227.

Cornerstone Financial Management first reported a position in TRDA in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.15K in Q1 2026. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Cornerstone Financial Management held 91 shares of Entrada Therapeutics worth $670 as of Q2 2026.
  • Cornerstone Financial Management left its Entrada Therapeutics share count unchanged in Q2 2026.
  • Entrada Therapeutics made up ﹤0.01% of Cornerstone Financial Management's portfolio in Q2 2026, its #1227 holding.
  • Cornerstone Financial Management first reported a position in Entrada Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Cornerstone Financial Management's Entrada Therapeutics position peaked at $1.15K in Q1 2026.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Cornerstone Financial Management's 13F filing for Q2 2026, filed 12 Aug 2026.